COVID-19 vaccination in South Korea

Last updated

COVID-19 vaccination in South Korea
South Korea Doses Given by Province map per population (as of 1st of July).png
South Korea. Percentage with total doses given as of 9 November 2023. [1]
Date26 February 2021 (2021-02-26) – 13 April 2023 (2023-04-13)
Location South Korea
Cause COVID-19 pandemic in South Korea

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

Vaccination program

Daily updates are provided by Korea Disease Control and Prevention Agency. [2]


Vaccines delivered per pharmaceutical company as of 17 May 2024 [refresh]

  Pfizer-BioNTech (11,488,000) (46.10%)
  Oxford-AstraZeneca (11,268,000) (45.22%)
  Moderna (1,151,000) (4.62%)
  Janssen (1,012,800) (4.06%)

As of 5 July 2021, due to vaccine shortages, the vaccination rate has been slowed down since 20 June. The vaccination rate remains 29% for more than two weeks. [3] According to JoongAng Ilbo, as of 5 July, the remaining amount of the COVID-19 vaccine is 1.8 million doses, including 1.4 million from Pfizer. [4]

On 6 July 2021, it is reported that South Korea has signed a deal with Israel to borrow 700,000 expiring doses of the Pfizer-BioNTech's vaccine. South Korea will return the same amount of vaccines to Israel around September or October of this year. [4] [5]

On 29 November 2021, President Moon Jae-in urged the rapid administration of booster shots against COVID-19, in response to an increased number of severe cases and deaths following the easing of anti-virus rules. [6]

Background

On 10 February 2021, South Korea granted its first approval of a COVID-19 vaccine to Oxford–AstraZeneca, allowing the two-shot regimen to be administered to all adults, including the elderly. The approval came with a warning, however, that consideration is needed when administering the vaccine to individuals over 65 years of age due to limited data from that demographic in clinical trials. [7] [8]

On 14 April 2021, The additional 250,000 doses of Pfizer/BioNTech vaccines arrived in the country. [9]

On 3 June 2021, the United States donated one million doses of Johnson & Johnson's vaccine to South Korea. The United States initially announced to donate 550,000 doses to South Korean troops working in close contact with American forces. [10] [11]

On 19 August 2021, Romania decided to donate 450,000 expiring Moderna vaccines to South Korea. [12]

Vaccines on order

Vaccine doseProgressDoses orderedManufacturerRemarks
Oxford-AstraZeneca Approved for use20 million Flag of South Korea.svg SK Bioscience -
up to 2.6 million Flag of South Korea.svg SK Bioscience
Flag of Italy.svg Catalent 		COVAX
Pfizer–BioNTech Approved for use96 million Flag of Belgium (civil).svg Pfizer -
up to 0.4 million Flag of Belgium (civil).svg Pfizer COVAX
0.7 million Flag of Belgium (civil).svg Pfizer Vaccine swap from Israel [13]
1 million Flag of Belgium (civil).svg Pfizer Vaccine swap from Romania
Janssen Approved for use6 million Flag of the United States.svg Emergent BioSolutions -
1.4 millionAn offer from the United States [14]
Moderna Approved for use40 million Flag of Switzerland (Pantone).svg Lonza
Flag of South Korea.svg Samsung Biologics 		-
0.4 million Flag of Switzerland (Pantone).svg Lonza An offer from Romania
Novavax Approved for use40 million Flag of South Korea.svg SK Bioscience -
Sputnik V Pre-reviewNone Flag of South Korea.svg Hankook Korus Pharm-
SKYCovione Approved for use10 million Flag of South Korea.svg SK Bioscience -

Timetable

VaccineManufacturerSubmitted EUA ApprovalDeployment
Green check.svg Oxford-AstraZeneca Flag of South Korea.svg SK Bioscience 4 January 2021None10 February 2021 [15] 26 February 2021 [16]
Flag of Italy.svg Catalent 4 January 202112 May 202121 May 202114 May 2021
Green check.svg Pfizer–BioNTech Flag of Belgium (civil).svg Pfizer 25 January 20213 February 2021 [17] 5 March 2021 [18] 27 February 2021 [19]
Green check.svg Janssen Flag of the United States.svg Emergent BioSolutions 27 February 2021None7 April 2021 [20] 10 June 2021 [21]
Green check.svg Moderna Flag of Switzerland (Pantone).svg Lonza 12 April 2021None21 May 2021 [22] 17 June 2021 [23]
Flag of South Korea.svg Samsung Biologics PendingPendingPendingPending
Novavax Flag of South Korea.svg SK Bioscience PendingPendingPendingPending

Production

AstraZeneca signed a deal with South Korea's SK Bioscience to manufacture its vaccine products. The collaboration calls for the SK Bioscience to manufacture AZD1222 for local and global markets. [24] The World Health Organization approved AstraZeneca's COVID-19 vaccine for emergency use on February. The initial approval covers doses produced by AstraZeneca and South Korea's SK Bioscience. [25]

South Korea's Korus Pharm has formed a consortium to produce Russia's Sputnik V COVID-19 vaccine. the consortium will produce 500 million doses of the vaccine. [26] However, The Sputnik V doses manufactured in South Korea are not for domestic use. [27] The vaccine is to be exported to Russia and UAE. [28]

Novavax will license out its NVX-CoV2373 vaccine technology to SK Bioscience for contract manufacturing purposes. SK Bioscience will manufacture 40 million doses of Novavax vaccines. [29]

Vaccines in trial stage

On 9 November 2023, SK Bioscience submitted investigational new drug for GBP510 COVID-19 vaccine candidate to Korea Ministry of Food and Drug Safety, for Phase III clinical trial. SK Bioscience plans its Phase III trial in form of comparative effectiveness clinical trial, targeting 4,000 people in South Korea.

VaccineType (technology)Phase IPhase IIPhase III
INO-4800 DNAGreen check.svg CompletedGreen check.svg CompletedIn progress
GX-19 (GX-19N)DNAGreen check.svg CompletedIn progressIn progress
EuCorVac-19 SubunitGreen check.svg CompletedIn progressDark Red x.svg Not Yet
GBP510 SubunitGreen check.svg CompletedGreen check.svg CompletedIn progress
AdCLD-CoV19 Viral vectorGreen check.svg CompletedIn progressDark Red x.svg Not Yet
GLS-5310DNAGreen check.svg CompletedIn progressDark Red x.svg Not Yet
NBP2001SubunitGreen check.svg CompletedDark Red x.svg Not YetDark Red x.svg Not Yet
EG-COVIDmRNAIn progressIn progressDark Red x.svg Not Yet
IN-B009SubunitIn progressDark Red x.svg Not YetDark Red x.svg Not Yet

Related Research Articles

The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health and Aged Care, the TGA regulates the quality, supply and advertising of medicines, pathology devices, medical devices, blood products and most other therapeutics. Any items that claim to have a therapeutic effect, are involved in the administration of medication, or are otherwise covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order, must be approved by the TGA and registered in the Australian Register of Therapeutic Goods.

Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company, based in Pune. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.

<span class="mw-page-title-main">Oxford–AstraZeneca COVID-19 vaccine</span> Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.

<span class="mw-page-title-main">COVID-19 vaccination in the United Kingdom</span> Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom.

The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.

<span class="mw-page-title-main">COVID-19 vaccination in Australia</span> Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Albania</span>

The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Canada</span> COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.

<span class="mw-page-title-main">COVID-19 vaccination in South Africa</span> Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Africa</span> Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.

<span class="mw-page-title-main">COVID-19 vaccination in Vietnam</span> Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Mexico</span> Plan to immunize against COVID-19

COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Indonesia</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.

<span class="mw-page-title-main">COVID-19 vaccination in Bangladesh</span> Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Sri Lanka</span> Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

<span class="mw-page-title-main">COVID-19 vaccination in Taiwan</span> Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">Skycovione</span> Vaccine candidate against COVID-19

Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, It is South Korea's first homegrown COVID-19 vaccine and utilizes GSK's AS03 adjuvant technology.

References

  1. ↑ South Korea COVID-19 Vaccine Tracker: Provinces Map Archived 29 June 2021 at the Wayback Machine . By George Karabassis Archived 14 April 2022 at the Wayback Machine .
  2. ↑ "코로나19 백신 및 예방접종: 안전하고, 신속하게 추진합니다" (Press release) (in Korean). Korea Disease Control and Prevention Agency. Archived from the original on 19 June 2021. Retrieved 19 June 2021.
  3. ↑ "어제 1차 접종자 '0명'… 백신 부족에 접종속도 급격히 느려져" [Yesterday's 1st vaccination '0'... Vaccination rate is rapidly slowed]. Asian Economy. 5 July 2021. Archived from the original on 9 July 2021. Retrieved 6 July 2021.
  4. 1 2 "백신 보릿고개 韓, 기한 다된 이스라엘 화이자 백신 빌린다" [Vaccine shortage, Korea borrows expiring Pfizer vaccine from Israel]. JoongAng Ilbo . 7 July 2021. Archived from the original on 9 July 2021. Retrieved 6 July 2021.
  5. ↑ "Israel, South Korea strike COVID vaccine exchange deal". The Jerusalem Post. 6 July 2021. Archived from the original on 6 July 2021. Retrieved 6 July 2021.
  6. ↑ "S.Korean president urges rapid administration of booster shots against COVID-19". www.news.cn. Archived from the original on 29 November 2021. Retrieved 29 November 2021.
  7. ↑ Kim, Han-joo (10 February 2021). "S. Korea approves AstraZeneca's COVID-19 vaccine for all adults". Yonhap News Agency . Archived from the original on 13 February 2021. Retrieved 10 February 2021.
  8. ↑ Maresca, Thomas (10 February 2021). "South Korea approves AstraZeneca COVID-19 vaccine". UPI. Archived from the original on 12 March 2021. Retrieved 10 February 2021.
  9. ↑ "Coronavirus: South Korea warns of possible fourth wave, Thailand cases surge". South China Morning Post. 14 April 2021. Archived from the original on 24 April 2021. Retrieved 18 April 2021.
  10. ↑ "U.S. Will Provide Covid-19 Vaccines to 550,000 South Korean Troops Engaged With U.S. Forces". The Wall Street Times. 21 May 2021. Archived from the original on 6 July 2021. Retrieved 6 July 2021.
  11. ↑ "U.S. Vaccines Ship to South Korea as Donations Start to Flow". Bloomberg.com. Bloomberg. 4 June 2021. Archived from the original on 9 July 2021. Retrieved 6 July 2021.
  12. ↑ "Romania donates 450,000 Moderna vaccines to South Korea". MSN. 20 August 2021. Archived from the original on 21 August 2021. Retrieved 21 August 2021.
  13. ↑ Dasl Yoon, Dov Lieber (6 July 2021). "World's First Covid-19 Vaccine Swap Sends Israel's Expiring Supply to South Korea". The Wall Street Journal. Archived from the original on 21 July 2021. Retrieved 28 July 2021.
  14. ↑ Hyonhee Shin (30 May 2021). "South Korea says 1 million doses of J&J COVID-19 vaccines to arrive this week from U.S." Reuters.
  15. ↑ Maresca, Thomas (10 February 2021). "South Korea approves AstraZeneca COVID-19 vaccine". UPI. Archived from the original on 12 March 2021. Retrieved 28 February 2021.
  16. ↑ Kim, Tong-hyung (26 February 2021). "South Korea starts vaccinating, but people over 65 must wait". ABC News. Archived from the original on 27 February 2021. Retrieved 28 February 2021.
  17. ↑ Lim, Jeong-yeo (3 February 2021). "South Korea approves special import of Pfizer vaccine". The Korea Herald . Archived from the original on 16 February 2021. Retrieved 28 February 2021.
  18. ↑ Kim, Han-joo (5 March 2021). "S. Korea approves Pfizer's COVID-19 vaccine amid immunization push". Yonhap News Agency . Archived from the original on 10 March 2021. Retrieved 5 March 2021.
  19. ↑ Lee, Kyung-eun (27 February 2021). "S. Korea begins rolling out Pfizer vaccines on second day of national vaccination program". Arirang News. Archived from the original on 10 March 2021. Retrieved 28 February 2021.
  20. ↑ "S. Korea approves Janssen's COVID-19 vaccine". Yonhap News Agency . 7 April 2021. Archived from the original on 7 April 2021. Retrieved 8 April 2021.
  21. ↑ "Koreans begin to get Janssen vaccine amid rising hope of normal life". Yonhap News Agency . 10 June 2021. Archived from the original on 10 June 2021. Retrieved 10 June 2021.
  22. ↑ Kim, Han-joo (21 May 2021). "Moderna COVID-19 vaccine gets final nod in S. Korea". Yonhap News Agency . Archived from the original on 21 May 2021. Retrieved 21 May 2021.
  23. ↑ Hwangbo, Hye-gyeong (17 June 2021). "모더나 국내 첫 접종 시작..."1차 1,400만 명 넘을 것"". YTN (in Korean). Archived from the original on 16 May 2024. Retrieved 28 July 2021.
  24. ↑ Kim, Yoo-chul (30 November 2020). "Korea signs agreement with AstraZeneca for COVID vaccine". The Korea Times . Archived from the original on 17 February 2021. Retrieved 30 January 2021.
  25. ↑ Steinhauser, Gabriele (15 February 2021). "WHO Approves AstraZeneca Covid-19 Vaccine for Emergency Use". The Wall Street Journal. Archived from the original on 28 February 2021. Retrieved 1 March 2021.
  26. ↑ Choi, Moon-hee (26 February 2021). "South Korean Companies to Produce Russia's Sputnik V Vaccine". Businesskorea. Archived from the original on 5 March 2021. Retrieved 1 March 2021.
  27. ↑ Shim, Elizabeth (25 February 2021). "South Korean consortium to make 500 million doses of Sputnik V vaccine". UPI. Archived from the original on 24 April 2021. Retrieved 1 March 2021.
  28. ↑ Kim, Byeong-ho (23 February 2021). "주문량만 6억5000도스, 국내 생산 러 백신 공장 가보니". Maeil Business (in Korean). Archived from the original on 24 February 2021. Retrieved 1 March 2021.
  29. ↑ Lim, Jeong-yeo (16 February 2021). "SK Bioscience to manufacture Novavax vaccine for 20 mil population". The Korea Herald. Archived from the original on 18 February 2021. Retrieved 1 March 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.